

Aldona Kowalska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/309786/publications.pdf>

Version: 2024-02-01

60
papers

1,059
citations

430754

18
h-index

454834

30
g-index

61
all docs

61
docs citations

61
times ranked

1752
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>CHEK2</i> mutations and the risk of papillary thyroid cancer. <i>International Journal of Cancer</i> , 2015, 137, 548-552.	2.3	97
2	Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH ₂]-exendin-4 for the detection of insulinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 524-531.	3.3	96
3	Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. <i>European Journal of Cancer</i> , 2017, 77, 140-152.	1.3	72
4	Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer. <i>Genes</i> , 2019, 10, 482.	1.0	62
5	Telomeres and telomerase in oncogenesis (Review). <i>Oncology Letters</i> , 2020, 20, 1015-1027.	0.8	59
6	The <i>BRAF</i> ^{V600E} mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?. <i>Clinical Endocrinology</i> , 2014, 80, 899-904.	1.2	52
7	Zalecenia ogólnie dotyczące postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polskie Towarzystwo Guzów) Tj ETQq1 1 0.78431408 BT / Overlock 10		
8	Testing new susceptibility genes in the cohort of apparently sporadic pheochromocytoma/paraganglioma patients with clinical characteristics of hereditary syndromes. <i>Clinical Endocrinology</i> , 2013, 79, 817-823.	1.2	38
9	Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the <i>BRAF</i> ^{V600E} Mutation: A Single-Institution Study. <i>Thyroid</i> , 2016, 26, 543-551.	2.4	34
10	Rekomendacje Polskich Towarzystw Naukowych – Diagnostyka i leczenie raka tarczycy – Aktualizacja na rok 2018. <i>Endokrynologia Polska</i> , 2018, 69, 34-74.	0.3	32
11	The impact of BMI on clinical progress, response to treatment, and disease course in patients with differentiated thyroid cancer. <i>PLoS ONE</i> , 2018, 13, e0204668.	1.1	30
12	99mTc Labeled Glucagon-Like Peptide-1-Analogue (99mTc-GLP1) Scintigraphy in the Management of Patients with Occult Insulinoma. <i>PLoS ONE</i> , 2016, 11, e0160714.	1.1	30
13	The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer. <i>PLoS ONE</i> , 2015, 10, e0133852.	1.1	24
14	The Delayed Risk Stratification System in the Risk of Differentiated Thyroid Cancer Recurrence. <i>PLoS ONE</i> , 2016, 11, e0153242.	1.1	24
15	Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer. <i>Endocrinology</i> , 2019, 160, 2328-2338.	1.4	22
16	Coexisting Germline CHEK2 and Somatic BRAFV600E Mutations in Papillary Thyroid Cancer and Their Association with Clinicopathological Features and Disease Course. <i>Cancers</i> , 2019, 11, 1744.	1.7	21
17	Nowotwory neuroendokrynne – dka i dwunastnicy z uwzględnieniem gastrinoma (zasady postępowania) Tj ETQq1 1 0.78431408 BT / Overlock 10	0.3	20
18	Nowotwory neuroendokrynne jelita grubego – zasady postępowania (rekomendowane przez Polskie Towarzystwo Guzów) Tj ETQq0 0,0 rgBT / Ov	0.3	20

#	ARTICLE	IF	CITATIONS
19	Response to therapy of papillary thyroid cancer of known <i>BRAF</i> status. <i>Clinical Endocrinology</i> , 2017, 87, 815-824.	1.2	19
20	Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego – zasady postępowania (rekomendowane przez Polsk... Sieć Guzów Neuroendokrynnych). <i>Endokrynologia Polska</i> , 2017, 68, 223-236.	0.3	18
21	Immunohistochemistry cannot replace DNA analysis for evaluation of <i>BRAF</i> V600E mutations in papillary thyroid carcinoma. <i>Oncotarget</i> , 2017, 8, 74897-74909.	0.8	16
22	Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a problematic entity. <i>Endocrine Connections</i> , 2020, 9, R47-R58.	0.8	15
23	The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan. <i>Nuclear Medicine Review</i> , 2014, 17, 87-93.	0.3	15
24	Papillary Thyroid Cancer in a Struma Ovarii in a 17-Year-Old Nulliparous Patient: A Case Report. <i>Diagnostics</i> , 2020, 10, 45.	1.3	14
25	The p.G534E variant of <i>HABP2</i> is not associated with sporadic papillary thyroid carcinoma in a Polish population. <i>Oncotarget</i> , 2017, 8, 58304-58308.	0.8	14
26	The clinical course of poorly differentiated thyroid carcinoma (insular carcinoma) - own observations. <i>Endokrynologia Polska</i> , 2010, 61, 467-73.	0.3	14
27	Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults. <i>European Journal of Endocrinology</i> , 2018, 179, 169-179.	1.9	11
28	Measurement of 131I activity in air indoor Polish nuclear medical hospital as a tool for an internal dose assessment. <i>Radiation and Environmental Biophysics</i> , 2018, 57, 77-82.	0.6	10
29	Effective Preoperative Plasmapheresis Treatment of Severe Hyperthyroidism in a Patient with Giant Toxic Nodular Goiter and Methimazole-Induced Agranulocytosis. <i>Medicina (Lithuania)</i> , 2020, 56, 290.	0.8	10
30	Assessment of the nuclear medicine personnel occupational exposure to radioiodine. <i>European Journal of Radiology</i> , 2019, 121, 108712.	1.2	9
31	Poorly differentiated thyroid cancer in the context of the revised 2015 American Thyroid Association Guidelines and the Updated American Joint Committee on Cancer/Tumorâ€Metastasis Staging System (eighth edition). <i>Clinical Endocrinology</i> , 2019, 91, 331-339.	1.2	9
32	Evaluation of molecular diagnostic approaches for the detection of <i>BRAF</i> p.V600E mutations in papillary thyroid cancer: Clinical implications. <i>PLoS ONE</i> , 2017, 12, e0179691.	1.1	9
33	Delayed risk stratification system in pT1aN0/Nx DTC patients treated without radioactive iodine. <i>Endocrine Connections</i> , 2017, 6, 522-527.	0.8	8
34	PrzydatnoÅł okreÅłania obecnoÅci mutacji <i>BRAF</i> V600E w biopsji aspiracyjnej celowanej cienkoigÅłowej w zmianach niezdeteminowanych. <i>Endokrynologia Polska</i> , 2016, 67, 41-47.	0.3	8
35	Coexistence of macroprolactinaemia and hyperprolactinaemia in women with oligo-/amenorrhoea is associated with high risk of pituitary adenomas. <i>Gynecological Endocrinology</i> , 2014, 30, 385-387.	0.7	7
36	Snail-1 Overexpression Correlates with Metastatic Phenotype in <i>BRAF</i> V600E Positive Papillary Thyroid Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 2701.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Did Introducing a New Category of Thyroid Tumors (Non-invasive Follicular Thyroid Neoplasm with) Tj ETQq1 1 0.784314 rgBT /Overlock Bethesda System for Reporting Thyroid Cytopathology?. <i>Endocrine Pathology</i> , 2020, 31, 143-149.	5.2	7
38	Immune Profiling of Medullary Thyroid Cancer—An Opportunity for Immunotherapy. <i>Genes</i> , 2021, 12, 1534.	1.0	7
39	The current state and future perspectives of high intensity focused ultrasound (HIFU) ablation for benign thyroid nodules. <i>Gland Surgery</i> , 2020, 9, S95-S104.	0.5	6
40	Incidence of the CHEK2 Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma. <i>Cancers</i> , 2021, 13, 470.	1.7	6
41	Is Male Sex A Prognostic Factor in Papillary Thyroid Cancer?. <i>Journal of Clinical Medicine</i> , 2021, 10, 2438.	1.0	6
42	Histopathology and immunohistochemistry as prognostic factors for poorly differentiated thyroid cancer in a series of Polish patients. <i>PLoS ONE</i> , 2020, 15, e0229264.	1.1	5
43	Variation of the epidemiological structure of thyroid cancer between year 2000 and 2012. <i>Thyroid Research</i> , 2013, 6, .	0.7	4
44	Repeated nondiagnostic result of thyroid fine-needle aspiration biopsy. <i>Wspolczesna Onkologia</i> , 2016, 6, 491-495.	0.7	4
45	Wolne i biodostępne frakcje steroidów płciowych mogą... wpływać na kości u młodych mężczyzn w zależności od wieku i stosowania estradiolu. <i>Endokrynologia Polska</i> , 2014, 65, 357-364.	0.3	4
46	The influence of the reclassification of NIFTP as an uncertain tumour on risk of malignancy for the diagnostic categories according to the Bethesda system for reporting thyroid cytopathology. <i>Endokrynologia Polska</i> , 2019, 70, 232-236.	0.3	4
47	Does the TT Variant of the rs966423 Polymorphism in DIRC3 Affect the Stage and Clinical Course of Papillary Thyroid Cancer?. <i>Cancers</i> , 2020, 12, 423.	1.7	3
48	Prevalence of macroprolactinaemia in regularly menstruating women with non-toxic goitre or autoimmune thyroid disease. <i>Thyroid Research</i> , 2012, 5, 20.	0.7	1
49	Late-Onset Medullary Thyroid Cancer in a Patient with a Germline RET Codon C634R Mutation. <i>Diagnostics</i> , 2021, 11, 1448.	1.3	1
50	High sensitivity of BRAF detection method does not alter response to therapy of papillary thyroid cancer of known BRAF status. <i>Endocrine Abstracts</i> , 0, .	0.0	1
51	Unusual case of radioactive iodine induced Graves disease with orbitopathy following total thyroidectomy in a patient with papillary thyroid microcarcinoma. <i>Endokrynologia Polska</i> , 2020, 71, 277-278.	0.3	1
52	Genotoxicity Associated with 131I and 99mTc Exposure in Nuclear Medicine Staff: A Physical and Biological Monitoring Study. <i>Cells</i> , 2022, 11, 1655.	1.8	1
53	Diagnosis of thyroid tumours in Świętokrzyskie Province in Poland with respect to the regulations provided in the new oncological package. <i>Pediatrics I Medycyna Rodzinna</i> , 2017, 13, 491-497.	2.3	0
54	Impact of non-invasive follicular thyroid neoplasms with papillary-like nuclear features on risk of malignancy. <i>European Journal of Endocrinology</i> , 2019, 181, L7-L8.	1.9	0

#	ARTICLE	IF	CITATIONS
55	Two cases of pheochromocytoma in pregnancy: a multidisciplinary challenge. <i>Endokrynologia Polska</i> , 2020, 71, 98-99.	0.3	0
56	Occurrence of Arrhythmias in Women with Thyroid Cancer Receiving Suppressive Doses of Levothyroxine. <i>Current Oncology</i> , 2021, 28, 5009-5018.	0.9	0
57	Title is missing!., 2020, 15, e0229264.		0
58	Title is missing!., 2020, 15, e0229264.		0
59	Title is missing!., 2020, 15, e0229264.		0
60	Title is missing!., 2020, 15, e0229264.		0